Steroid-refractory hand eczema: treatment experience

Hand eczema is a common multi-etiological disease manifested by evolutionary polymorphism of rashes. Hand eczema develops against the background of altered reactivity and genetic predisposition under the adverse effects of endogenous and exogenous factors. Hand eczema has a chronic course and is characterized by a wide range of clinical manifestations. The prevalence of eczematous lesions of the hands among the adult population is 1–2%, and among all skin diseases – 30–40%. The disease has an extremely negative impact on the quality of life, ability to work, career prospects and the social status of a person. The long course of eczematous lesions of the hands can be complicated by a secondary infection: bacterial and mycotic flora. Therefore, choosing the right and effective treatment for hand eczema is a particularly difficult task for a dermatologist. In recent years, a multicomponent drug based on gentamicin sulfate, dexpanthenol, mometasone furoate and econazole nitrate has been widely used for the treatment of hand eczema due to its high efficacy, tolerability, and safety. The use of this multicomponent drug in monotherapy for hand eczema is effective, leads to clinical remission and restoration of the quality of life of patients and is not accompanied by side effects and complications. This review focuses on the epidemiology, clinical features, and treatment options for hand eczema. Clinical experience with the use of a multicomponent drug in patients with hand eczema complicated by infection is also given.

1. Christoffers W.A., Coenraads P.-J., Svensson А., Diepgen T.L., Dickinson-Blok J.L., Xia J., Williams H.C. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4(4):CD004055. https://doi.org/10.1002/14651858.CD004055.pub2.

2. Appelen D., Romijn-Bucarciuc D., Stenveld H., Visch M.B. Hand eczema in COVID-19 outbreak: whether or not to wear gloves? Ned Tijdschr Geneeskd. 2020;164:D5252. Available at: https://www.ntvg.nl/artikelen/handeczeem-tijden-van-corona.

3. Thyssen J.P., Johansen J.D., Linneberg A., Menné T. The epidemiology of hand eczema in the general population – prevalence and main findings. Contact Dermatitis. 2010;62(2):75–87. https://doi.org/10.1111/j.1600-0536.2009.01669.x.

4. Diepgen T.L., Andersen K.E., Chosidow O., Coenraads P.J., Elsner P., English J. et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1–e22. https://doi.org/10.1111/ddg.12510_1.

5. Diepgen Т.L., Pfarr Е., Zimmermann Т. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012;92(3):251–255. https://doi.org/10.2340/00015555-1256.

6. Cazzaniga S., Apfelbacher C., Diepgen T., Ofenloch R.F., Weisshaar E., Molinet S. et al. Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. Br J Dermatol. 2018;178(1):229–237. https://doi.org/10.1111/bjd.15660.

7. Elston D.M., Ahmed D.D.F., Watsky K.L., Schwarzenberger K. Hand dermatitis. J Am Acad Dermatol. 2002;47(2):291–299. https://doi.org/10.1067/mjd.2002.122757.

8. Scalone L., Cortesi P.A., Mantovani L.G., Belisari A., Ayala F., Fortina A.B. et al. Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: Results from Italy. Br J Dermatol. 2015;172(1):187–195. https://doi.org/10.1111/bjd.13220.

9. Apfelbacher C., Molin S., Weisshaar E., Bauer A., Elsner P., Mahler V. et al. Characteristics and provision of care in patients with chronic hand eczema: Updated data from the CARPE registry. Acta Derm Venereol. 2014;94(2):163–167. https://doi.org/10.2340/00015555-1632.

10. Salvador S.J.F., Mendaza F.H., Garcés M.H., Palacios-Martínez D., Sánchez Camacho R., Sanzet R.S. et al. Guidelines for the Diagnosis, Treatment, and Prevention of Hand Eczema. Actas Dermosifiliogr (Engl Ed). 2020;111(1):26–40. https://doi.org/10.1016/j.ad.2019.04.005.

11. Agner T., Aalto-Korte K., Andersen K.E., Foti C., Gimenéz-Arnau A., Goncalo M. et al. Classification of hand eczema. J Eur Acad Dermatol Venereol. 2015;29(12):2417–2422. https://doi.org/10.1111/jdv.13308.

12. Thyssen J.P., Schuttelaar M.L.A., Alfonso J.H., Andersen K.E., Angelova-Fischer I., Arents B.M.W. et al. Guidelines for diagnosis, prevention and treatment of hand eczema. Contact Dermatitis. 2021. https://doi.org/10.1111/cod.14035.

13. Coenraads P.-J. Hand eczema. N Engl J Med. 2012;367(19):1829–1837. https://doi.org/10.1056/NEJMcp1104084.

14. Sarmiento P.M.C., Azanza J.J.C. Dyshidrotic Eczema: A Common Cause of Palmar Dermatitis. Cureus. 2020;12(10):e10839. https://doi.org/10.7759/cureus.10839.

15. Wollina U. Pompholyx: a review of clinical features, differential diagnosis, and management. Am J Clin Dermatol. 2010;11(5):305–314. https://doi.org/10.2165/11533250-000000000-00000.

16. Minocha Y.C., Dogra A., Sood V.K. Contact sensitivity in palmer hyperkeratotic dermatitis. Indian J Dermatol Venerol Leprol. 1993;59:60–63. Available at: https://ijdvl.com/contact-sensitivity-in-palmar-hyperkeratotic-dermatitis/.

17. Nielsen J. The occurrence and course of skin symptoms on the hands among female cleaners. Contact Dermatitis. 1996;34(4):284–291. https://doi.org/10.1111/j.1600-0536.1996.tb02201.x.

18. Reinholz M., Kendziora B., Frey S., Oppel E.M., Ruëff F., Clanner-Engelshofen B.M. et al. Increased prevalence of irritant hand eczema in health care workers in a dermatological clinic due to increased hygiene measures during the SARS-CoV-2 pandemic. Eur J Dermatol. 2021;31(3):392–395. https://doi.org/10.1684/ejd.2021.4046.

19. Singh M., Pawar M., Bothra A., Choudhary N. Overzealous hand hygiene during the COVID 19 pandemic causing an increased incidence of hand eczema among general population. J Am Acad Dermatol. 2020;83(1):e37–e41. https://doi.org/10.1016/j.jaad.2020.04.047.

20. Berents T.L., Saunes M., Schopf T., Vindenes H.K. Atopisk eksem. Tidsskr Nor Laegeforen. 2018;138(13). https://doi.org/10.4045/tidsskr.18.0071.

21. Leung A.K.C., Lam J.M., Leong K.F., Leung A.A.M., Wong A.H.C., Hon K.L. Nummular Eczema: An Updated Review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(2):146–155. https://doi.org/10.2174/1872213X14666200810152246.

22. Crane M.M., Webb D.J., Watson E., Cunliffe T., English J. Hand eczema and steroid-refractory chronic hand eczema in general practice: prevalence and initial treatment. Br J Dermatol. 2017;176(4):955–964. https://doi.org/10.1111/bjd.14974.

23. Berthold E., Weisshaar E. Treatment of hand eczema. Hautarzt. 2019;70(10):790–796. https://doi.org/10.1007/s00105-019-04475-4.

24. Dubin С., Del Duca Е., Guttman-Yassky Е. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319–1332. https://doi.org/10.2147/TCRM.S292504.

25. De León F.J., Berbegal L., Silvestre J.F. Management of Chronic Hand Eczema. Actas Dermosifiliogr. 2015;106(7):533–544. https://doi.org/10.1016/j.ad.2015.04.005.

26. Kao J.S., Fluhr J.W., Man M.-Q., Fowler A.J., Hachem J.-P., Crumrine D. et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120(3):456–464. https://doi.org/10.1046/j.1523-1747.2003.12053.x.

27. Guenther L., Lynde C., Poulin Y. Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders. J Cutan Med Surg. 2019;23(4_suppl): 27S–34S. https://doi.org/10.1177/1203475419857668.

28. Song M., Lee H.-J., Lee W.-K. Kim H.-S., Ko H.-C., Kim M.-B., Kim B.-S. Acitretin as a Therapeutic Option for Chronic Hand Eczema. Annals of dermatology. 2017;29(3): 385–387. https://doi.org/10.5021/ad.2017.29.3.385.

29. Gritiyarangsan P., Sukhum A., Tresukosol P., Kullavanijaya P. Topical PUVA therapy for chronic hand eczema. J Dermatol. 1998;25(5):299–301. https://doi.org/10.1111/j.1346-8138.1998.tb02401.x.

30. Sezer E., Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed. 2007;23(1):10–14. https://doi.org/10.1111/j.1600-0781.2007.00258.x.

31. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol. 1999;41(3 Pt 2):S22–S4. https://doi.org/10.1016/s0190-9622(99)70362-2.

32. Haslund P., Bangsgaard N., Jarløv J.O., Skov L., Skov R., Agner T. Staphylococcus aureus and hand eczema severity. Br J Dermatol. 2009;161(4):772–777. https://doi.org/10.1111/j.1365-2133.2009.09353.x.

33. Mernelius S., Carlsson Е., Henricson J., Löfgren S., Lindgren P.-E., Ehricht R. et al. Staphylococcus aureus colonization related to severity of hand eczema. Eur J Clin Microbiol Infect Dis. 2016;35(8):1355–1361. https://doi.org/10.1007/s10096-016-2672-2.

34. Nørreslet L.B., Lilje B., Ingham A.C., Edslev S.M., Clausen M.-L., Plum F. et al. Skin Microbiome in Patients with Hand Eczema and Healthy Controls: A Three-week Prospective Study. Acta Derm Venereol. 2022;102:adv00633. https://doi.org/10.2340/actadv.v101.845.

35. Byrd A.L., Belkaid Y., Segre J.A. The human skin microbiome. Nat Rev Microbiol. 2018;16(3):143–155. https://doi.org/10.1038/nrmicro.2017.157.

36. Bay L., Ring H.C. Human skin microbiota in health and disease: The cutaneous communities’ interplay in equilibrium and dysbiosis: The cutaneous communities’ interplay in equilibrium and dysbiosis. APMIS. 2021. https://doi.org/10.1111/apm.13201.

37. Nikonova I.V., Orlov E.V., Konnov P.E. Condition of biocenosis skin at microbial eczema. Practical Medicine. 2011;2(49):80–83. (In Russ.) Available at: https://cyberleninka.ru/article/n/sostoyanie-biotsenoza-kozhi-primikrobnoy-ekzeme/viewer.

38. Petrovsky F.I., Korostovtsev D.S. Activated zinc pyrithione application for the atopic dermatitis among children: mechanism of action, clinical efficiency. Pediatric Pharmacology. 2009;6(2):67–71. (In Russ.) Available at: https://www.pedpharma.ru/jour/issue/viewIssue/53/38.

39. Moriwaki M., Iwamoto K., Niitsu Y., Matsushima A., Yanase Y., Hisatsune J. et al. Staphylococcus aureus from atopic dermatitis skin accumulates in the lysosomes of keratinocytes with induction of IL-1α secretion via TLR9. Allergy. 2019;74(3):560–571. https://doi.org/10.1111/all.13622.

40. Kubanov A.A., Khardikova S.A., Zaslavskiy D.V., Novikov Yu.A., Radul E.V., Pravdina O.V. et al. Eczema: clinical guidelines. Moscow; 2021. (In Russ.) Available at: https://cr.minzdrav.gov.ru/recomend/246_2.

41. Abou-Zeid A.A., Shehata Y.M. Gentamicins. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg. 1977;132(2):97–108. https://doi.org/10.1016/s0044-4057(77)80051-8.

42. Das М.С., Biswas А., Chowdhury M., Saha J. Screening Antimicrobial Susceptibility of Gentamicin, Vancomycin, Azithromycin, Chloramphenicol and Cefotaxime Against Selected Gram Positive and Gram Negative Bacteria. Int J Pharma Res Health Sci. 2014;2(4):324–331. Avaliable at: http://www.pharmahealthsciences.net/pdfs/VOLUME-2-ISSUE-42014/8_1485.pdf.

43. Naimi H.M, Rasekh H., Noori A.Z, Bahaduri M.A. Determination of antimicrobial susceptibility patterns in Staphylococcus aureus strains recovered from patients at two main health facilities in Kabul, Afghanistan. BMC Infect Dis. 2017;17(1):737. https://doi.org/10.1186/s12879-017-2844-4.

44. Simonetti N., Spignoli G., D’Auria F.D., Strippoli V. Antimicrobial contact activity of econazole sulfosalicylate. J Chemother. 1991;3(2):101–107. https://doi.org/10.1080/1120009x.1991.11739074.

45. Gorski J., Proksch E., Baron J.M., Schmid D., Zhang L. Dexpanthenol in Wound Healing after Medical and Cosmetic Interventions (Postprocedure Wound Healing). Pharmaceuticals (Basel). 2020;13(7):138. https://doi.org/10.3390/ph13070138.

46. Wiederholt T., Heise R., Skazik C., Marquardt Y., Joussen S., Erdmann K. et al. Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009;18(11):969–978. https://doi.org/10.1111/j.1600-0625.2009.00884.x.

47. Tlish M.M., Kuznetsova T.G., Naatyzh Z.Y., Psavok F.A. Microbial eczema: possibilities of correction at the present stage. Vestnik Dermatologii i Venerologii. 2018;94(4):60–67. (In Russ.) https://doi.org/10.25208/0042-4609-2018-94-4-60-67.

48. Kungurov N.V., Kokhan M.M., Keniksfest Yu.V., Kascheeva Ya.V., Letaeva O.V., Kuklin I.A., Stukova E.I. Innovative combined topical remedy in the treatment of complicated dermatoses: experience of the application. Lechaschi Vrach. 2019;5(19):38–49. (In Russ.) Available at: https://www.lvrach.ru/2019/05/15437294.

49. Yakovlev A.B., Kruglova L.S. Dyshydrosis and dyshydrotic dermatoses: characteristics of clinical presentation, diagnosis, and treatment. Klinicheskaya Dermatologiya i Venerologiya. 2018;17(4):72–78. (In Russ.) https://doi.org/10.17116/klinderma20181704172.

50. Kruglova L.S., Fyodorov D.V., Stenko A.G., Gryazeva N.V., Yakovlev A.B. Actual recommendations for multicomponent drug use in dermatology. Medical Alphabet. 2019;2(26):67–72. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-26(401)-67-72.

51. Shperling N.V., Shperling I.A., Yurkevich Yu.V. The effectiveness of external therapy of dyshidrotic eczema with a combined drug. Klinicheskaya Dermatologiya i Venerologiya. 2020;19(2):200–204. (In Russ.) https://doi.org/10.17116/klinderma202019021200.